Syndax Announces Participation in Upcoming Investor Conferences
Rhea-AI Summary
Syndax Pharmaceuticals (Nasdaq:SNDX) announced participation in several upcoming investor conferences featuring fireside chats with CEO Michael A. Metzger and the management team.
Events include TD Cowen’s Oncology Innovation Summit, the Jefferies Global Healthcare Conference, and the Goldman Sachs Global Healthcare Conference, with live and replay webcasts via Syndax’s investor website.
Positive
- None.
Negative
- None.
News Market Reaction – SNDX
In the May 20 session, SNDX gained 3.98%, reflecting a moderate positive market reaction. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:
- TD Cowen 7th Annual Oncology Innovation Summit with a virtual fireside chat on Wednesday, May 27, 2026, at 1:00 p.m. ET.
- Jefferies Global Healthcare Conference in New York, NY with a fireside chat on Thursday, June 4, 2026, at 9:20 a.m. ET.
- Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, FL, with a fireside chat on Monday, June 8, 2026, at 2:00 p.m. ET.
A live webcast of the fireside chats will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
